Evolving the supply chain to counter key challenges in apheresis and leukapheresis collectionPublished: December 4, 2019
Supply Chain Focus: Materials Collection & Logistics at the Clinical Point of Care
Peter Olagunju is the Vice President of Patient Operations with bluebird bio. In this role, Peter has responsibility for managing the CMC related Centers of Excellence (COE) interfaces including the collection of patient cells, manufacture of drug product, and operational execution of patient treatments. Prior to bluebird bio, Peter most recently served as Senior Director, Global Technical Operations at Valeant (through the acquisition of Dendreon). He was at Dendreon for roughly 5 years where he managed the US and EU manufacturing operations and supply chain, including contract manufacturers, external testing sites, and the apheresis network for those regions. Prior to Dendreon, Peter had leadership positions within the quality function at a monoclonal antibody organization (ZymoGenetics) that was acquired by BMS in 2011. Peter did his undergraduate studies at the University of Illinois and completed an MBA program at the Foster school of Business (University of Washington).DOI: 10.18609/cgti.2019.168
Citation: Cell & Gene Therapy Insights 2019; 5(12), 1615–1620.